These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11809215)

  • 1. Bayesian stopping rules for trials.
    Kulvichit K
    Lancet; 2002 Jan; 359(9300):77. PubMed ID: 11809215
    [No Abstract]   [Full Text] [Related]  

  • 2. Bayesian stopping rules for trials.
    Nicholl J; Goodacre S
    Lancet; 2002 Jan; 359(9300):76-7. PubMed ID: 11809213
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian interim analysis of randomised trials.
    Abrams KR; Jones DR
    Lancet; 1997 Jun; 349(9069):1911-2. PubMed ID: 9217779
    [No Abstract]   [Full Text] [Related]  

  • 7. Bayesian interim analysis of randomised trials.
    Fayers P
    Lancet; 1997 Jun; 349(9069):1911. PubMed ID: 9217778
    [No Abstract]   [Full Text] [Related]  

  • 8. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 4: One method.
    Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S11-7. PubMed ID: 21651993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation.
    Chen C; Chaloner K
    Stat Med; 2006 Sep; 25(17):2956-66. PubMed ID: 16345039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian interim statistical analysis of randomised trials.
    Brophy JM; Joseph L
    Lancet; 1997 Apr; 349(9059):1166-8. PubMed ID: 9113025
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al., Statistics in Medicine 2006; 25:55-70.
    Chappell R; Karrison T
    Stat Med; 2007 Jul; 26(15):3050-2; author reply 3052-4. PubMed ID: 17163577
    [No Abstract]   [Full Text] [Related]  

  • 14. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A covariate adjusted two-stage allocation design for binary responses in randomized clinical trials.
    Bandyopadhyay U; Biswas A; Bhattacharya R
    Stat Med; 2007 Oct; 26(24):4386-99. PubMed ID: 17348082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
    Halpern J; Brown BW; Hornberger J
    Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.
    Kpozèhouen A; Alioum A; Anglaret X; Van de Perre P; Chêne G; Salamon R
    Am J Epidemiol; 2005 Mar; 161(6):595-603. PubMed ID: 15746476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stopping rules, Bayesian reconstructions and sieves.
    Llacer J; Veklerov E; Nunez J
    Prog Clin Biol Res; 1991; 363():81-93. PubMed ID: 1989004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.